PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy

E-ISSN： 1875-5666|13|2|296-304

ISSN： 1566-5240

Source： Current Molecular Medicine, Vol.13, Iss.2, 2012-12, pp. : 296-304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TRAIL: A Potential Agent for Cancer Therapy

Current Molecular Medicine, Vol. 3, Iss. 8, 2003-12 ,pp. : 727-736

Bentham Science Publishers

Access to resources Recommend Favorite

Aberrant hypomethylation of the cancer–testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia

By Ortmann Christina

Annals of Hematology, Vol. 87, Iss. 10, 2008-10 ,pp. : 809-818

Springer Publishing Company

Access to resources Recommend Favorite

Transforming growth factor-beta: A target for cancer therapy

By Kelly Ronan J. Morris John C.

Journal of Immunotoxicology, Vol. 7, Iss. 1, 2010-03 ,pp. : 15-26

Informa Healthcare

Access to resources Recommend Favorite

Autophagy: A potential target for thyroid cancer therapy (Review)

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 661-665

Spandidos Publications

Access to resources Recommend Favorite

BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer

By Le pottier Laëtitia Bendaoud Boutahar Dueymes Maryvonne Daridon Capucine Youinou Pierre Shoenfeld Yehuda Pers Jacques-olivier

Journal of Clinical Immunology, Vol. 27, Iss. 3, 2007-05 ,pp. : 257-265

Springer Publishing Company

Access to resources Recommend Favorite